Incyte Corporation (INCY) News Headlines

▮ More

Date

Headline

2/13/2020 7:31:30 AM Incyte Q4 Adj. Operating Income Rises; Jakafi Revenues Up 23% - Quick Facts

2/13/2020 7:24:59 AM Incyte Corporation Q4 adjusted earnings of $0.65 per share

2/13/2020 7:09:06 AM Incyte Q4 GAAP EPS $0.51; Non-GAAP EPS $0.65

2/13/2020 7:02:48 AM Incyte Q4 19 Earnings Conference Call At 8:00 AM ET

2/11/2020 9:42:23 PM Lilly's Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation

1/30/2020 6:47:34 AM Eli Lilly, Incyte: Baricitinib Meets Primary Endpoint In BREEZE-AD5 Study

1/30/2020 6:16:32 AM Eli Lilly And Incyte Announce That Baricitinib Met Primary Endpoint In BREEZE-AD5

1/27/2020 6:57:19 AM Lilly : Study Meets Primary Endpoint Of 75% Improvement Of Skin Inflammation

1/27/2020 6:46:23 AM Eli Lilly And Incyte: Baricitinib Met Primary Endpoint In BREEZE-AD4 Study

1/13/2020 1:54:23 AM MorphoSys, Incyte Agree To Co-commercialize Tafasitamab In The U.S.

1/2/2020 9:49:58 PM DRRX Plunges On Psoriasis Trial Data, INCY Fails GRAVITAS-301 Test, AGRX Abuzz

12/14/2019 3:14:45 AM Are These Biotech Companies Buyout Candidates? Deal Or No Deal?

12/4/2019 7:33:01 AM Incyte To Present At Piper Jaffray Healthcare Conference; Webcast At 8:30 AM ET

10/29/2019 7:54:33 AM Incyte Q3 Profit Surges; Raises FY19 Jakafi Revenue Outlook - Quick Facts

10/29/2019 7:13:38 AM Incyte Q3 EPS $0.59 Vs $0.14 Last Year

10/29/2019 7:02:43 AM Incyte Q3 19 Earnings Conference Call At 8:00 AM ET

10/8/2019 6:47:00 AM Lilly To Present New Data For Taltz, Olumiant And Mirikizumab At 28th Annual EADV Congress

9/27/2019 8:22:03 AM Incyte Announces Positive Updated Results From Phase 2 Trial Of Pemigatinib

9/25/2019 7:43:36 AM Incyte Says First Patient Treated In Phase 3 Clinical Trial Program Of Ruxolitinib Cream In Patients With Vitiligo

9/25/2019 7:38:04 AM Incyte Says First Patient Treated In Phase 3 Clinical Trial Program On Ruxolitinib Cream